Christine Kollar
5 Papers
21 Citations
Christine Kollar is an academic researcher. The author has contributed to research in topics: Population & Metered-dose inhaler. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
•Journal Article
Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development
Colin Reisner,Chadwick J. Orevillo,Carlos Fernandez,Patrick Darken,Earl St Rose,Michael Golden,Tracy Fischer,Shannon Strom,Christine Kollar,Klaus F. Rabe +9 more
TL;DR: Pooled analyses of FEV 1 AUC 0-12 confirm GFF MDI 18/9.6 μg is the optimal dose, and is being progressed into Phase 3, and the dose responses of GP, FF and GFFMDI have been well characterized.
9
A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
TL;DR: This Phase IIb study investigated the safety and efficacy of four doses of the LAMA glycopyrronium delivered using co-suspension delivery technology via metered dose inhaler (MDI), and indicated that there was no advantage of GP MDI 28.4 μg versus placebo MDI for the proportion of patients achieving ≥12% improvement in FEV1.
•Journal Article
Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators
Leonardo M. Fabbri,Roberto Rodriguez-Roisin,Chadwick J. Orevillo,Carlos Fernandez,Patrick Darken,Earl St Rose,Christine Kollar,Colin Reisner +7 more
TL;DR: Pooled analyses of QTcF data from six studies demonstrate that GFF MDI 18/9.6 μg had no significant impact on QT cF supporting its selection and progression into Phase III.
2
•Journal Article
Integrated analyses of phase II safety data support the safety of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) and glycopyrrolate (GP) MDI (PT001) in COPD
Roberto Rodriguez-Roisin,Leonardo M. Fabbri,Chadwick J. Orevillo,Carlos Fernandez,Patrick Darken,Earl St Rose,Tracy Fischer,Christine Kollar,Colin Reisner +8 more
TL;DR: Data from pooled analyses of safety data from 6 chronic-dosing studies in patients with COPD support the safety and progression of GFFMDI 18/9.6 µg and GP MDI 18 µg administered twice daily into Phase III trials in patientsWith COPD.
1